Biotech news
Pharma
Biopharmaceutical company, Moderna, has announced that it will not enforce patents related to its COVID-19 vaccine while the pandemic is ongoing, and that it is prepared to license the patents to others after the pandemic is over. 12 October 2020
Pharma
South Africa and India have asked the World Trade Organization to cede some stipulations governing IP so that treatments to combat COVID-19 can become more widely available, particularly in low-income countries. 8 October 2020
Biotech
Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein. 6 October 2020
Americas
Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments. 6 October 2020
Americas
Antimicrobial company PureShield has accused its competitor Allied BioScience of infringing ten patents through the sale of a surface disinfectant, which claims protection against COVID-19 for up to seven days. 30 September 2020
Biotech
The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds. 21 September 2020
Americas
Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard. 21 September 2020
Biotech
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court. 21 September 2020
Americas
Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin. 16 September 2020
Biotech
In the fast-paced environment of life sciences, the need for the IP sector to take full advantage of potential and emerging innovations is paramount, as a LSPN Connect session discovered. 14 September 2020